» Articles » PMID: 37082886

Association of Frequent Hypermethylation with High Grade Histological Subtype in Lung Adenocarcinoma

Abstract

Lung adenocarcinoma is classified morphologically into five histological subtypes according to the WHO classification. While each histological subtype correlates with a distinct prognosis, the molecular basis has not been fully elucidated. Here we conducted DNA methylation analysis of 30 lung adenocarcinoma cases annotated with the predominant histological subtypes and three normal lung cases using the Infinium BeadChip. Unsupervised hierarchical clustering analysis revealed three subgroups with different methylation levels: high-, intermediate-, and low-methylation epigenotypes (HME, IME, and LME). Micropapillary pattern (MPP)-predominant cases and those with MPP components were significantly enriched in HME (p = 0.02 and p = 0.03, respectively). HME cases showed a significantly poor prognosis for recurrence-free survival (p < 0.001) and overall survival (p = 0.006). We identified 365 HME marker genes specifically hypermethylated in HME cases with enrichment of "cell morphogenesis" related genes; 305 IME marker genes hypermethylated in HME and IME, but not in LME, with enrichment "embryonic organ morphogenesis"-related genes; 257 Common marker genes hypermethylated commonly in all cancer cases, with enrichment of "regionalization"-related genes. We extracted surrogate markers for each epigenotype and designed pyrosequencing primers for five HME markers (TCERG1L, CXCL12, FAM181B, HOXA11, GAD2), three IME markers (TBX18, ZNF154, NWD2) and three Common markers (SCT, GJD2, BARHL2). DNA methylation profiling using Infinium data was validated by pyrosequencing, and HME cases defined by pyrosequencing results also showed the worse recurrence-free survival. In conclusion, lung adenocarcinomas are stratified into subtypes with distinct DNA methylation levels, and the high-methylation subtype correlated with MPP-predominant cases and those with MPP components and showed a poor prognosis.

Citing Articles

Research Progress of Liquid Biopsy Based on DNA Methylation in Tumor Diagnosis and Treatment.

Bao Y, Wang X, Zeng B, Shi Y, Huang Y, Huang Y Biomolecules. 2025; 14(12.

PMID: 39766341 PMC: 11727523. DOI: 10.3390/biom14121634.


Micropapillary structure: A natural tumor collective invasion model with enhanced stem-like properties.

Li S, Gao S, Qin L, Ding C, Qu J, Cui Y Cancer Sci. 2024; 116(2):308-321.

PMID: 39568148 PMC: 11786311. DOI: 10.1111/cas.16396.


RNA sequencing identifies lung cancer lineage and facilitates drug repositioning.

Zeng L, Zhang L, Li L, Liao X, Yin C, Zhang L PeerJ. 2024; 12:e18159.

PMID: 39346064 PMC: 11430167. DOI: 10.7717/peerj.18159.


Impact of lung adenocarcinoma subtypes on survival and timing of brain metastases.

Zhou C, Zhang X, Yan X, Xie H, Tan H, Song Y Front Oncol. 2024; 14:1433505.

PMID: 39290244 PMC: 11405152. DOI: 10.3389/fonc.2024.1433505.


Methylation-related differentially expressed genes as potential prognostic biomarkers for cervical cancer.

Chen Y, Zou Q, Chen Q, Wang S, Du Q, Mai Q Heliyon. 2024; 10(17):e36240.

PMID: 39263148 PMC: 11387271. DOI: 10.1016/j.heliyon.2024.e36240.


References
1.
Joehanes R, Just A, Marioni R, Pilling L, Reynolds L, Mandaviya P . Epigenetic Signatures of Cigarette Smoking. Circ Cardiovasc Genet. 2016; 9(5):436-447. PMC: 5267325. DOI: 10.1161/CIRCGENETICS.116.001506. View

2.
Nikolaidis G, Raji O, Markopoulou S, Gosney J, Bryan J, Warburton C . DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res. 2012; 72(22):5692-701. PMC: 3500566. DOI: 10.1158/0008-5472.CAN-12-2309. View

3.
Tsao M, Marguet S, Le Teuff G, Lantuejoul S, Shepherd F, Seymour L . Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. J Clin Oncol. 2015; 33(30):3439-46. PMC: 4606061. DOI: 10.1200/JCO.2014.58.8335. View

4.
Yoshizawa A, Motoi N, Riely G, Sima C, Gerald W, Kris M . Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011; 24(5):653-64. DOI: 10.1038/modpathol.2010.232. View

5.
Jiang L, Mino-Kenudson M, Roden A, Rosell R, Molina M, Flores R . Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis. Eur J Surg Oncol. 2019; 45(5):870-876. DOI: 10.1016/j.ejso.2019.02.006. View